Objectives: To evaluate outcomes of BAHA Connect 1 and BAHA Attract 1 implantations, and to examine the prognostic utility of a preimplantation Softband 1 -attached processor trial. Study Design: Retrospective case review Setting: Tertiary referral center. Patients: Patients who underwent Connect 1 (19 ears) and Attract 1 (25 ears) implantation between 2007 and 2017. Intervention: BAHA 1 implantation. Main Outcome Measures: Unaided air conduction (AC), bone conduction (BC), and speech reception thresholds (SRTs), as well as free field (FF) aided with Softband 1attached processor and with implant-attached processor thresholds. Results: Serviceable implant-attached processor PTA 0.5,1,2 kHz ( 35 dB HL) was achieved in 89 and 88% of the Connect 1 and the Attract 1 ears, respectively, while at 4 kHz this was achieved in 68 and 32% of the Connect 1 and the Attract 1 ears, respectively ( p ¼ 0.032). Significantly more Connect 1 ears showed alignment between FF aided with implant-attached processors thresholds and BC thresholds. The alignment between the Softband 1 -attached processors thresholds and implant-attached processors thresholds was similar in the two groups. Both groups exhibited similar positive improvement in the quality of life questionnaires Conclusions: Accessibility to sound with the implantattached processor is well predicted by the pre-implantation Softband 1 trial, both in the BAHA Connect 1 and in the BAHA Attract 1 ears. Hearing rehabilitation targets at 0.5, 1, and 2 kHz are met by most Connect 1 and Attract 1 ears, while at 4 kHz the outcome with Attract 1 is poorer. This information should be presented to the patient during consultation prior to a decision as to the type of BAHA 1 device to be implanted.
Background: Given an increase in the aging population and its impact on healthcare systems, policy makers for provision of health and social services are aiming to keep older adults in good health for longer, in other words towards 'healthy aging'. Our study objective is to show that rehabilitation with cochlear implant treatment in the elderly with hearing impairment improves the overall health-related quality of life and general well-being that translate into healthy aging. Methods: The multicentre, prospective, repeated measures, single-subject, clinical observational study will accrue 100 elderly, first-time, unilateral CI recipients (≥ 60 years) and analyze changes on specific measurement tools over ca. 20 months from preimplant to postimplant. Evaluations will consist of details collected through case history and interview questionnaires by clinicians, data logging, self-report questionnaires completed by the recipients and a series of commonly used audiometric measures and geriatric assessment tools. The primary indicator of changes in overall quality of life will be the HUI-3. Discussion: The protocol is designed to make use of measurement tools that have already been applied to the hearing-impaired population in order to compare effects of CI rehabilitation in adults immediately before their implantation, (pre-implant) and after gaining 1-1.5 years of experience (post-implant). The broad approach will lead to a greater understanding of how useful hearing impacts the quality of life in elderly individuals, and thus improves potentials for healthy aging. Outcomes will be described and analyzed in detail. Trial registration: This research has been registered in ClinicalTrials.gov (http://www.clinicaltrials.gov/), 7 March 2017 under the n°NCT03072862.
Introduction: Patients with air bone gaps can be treated with bone conducting hearing aids. The disadvantages of the conventional and percutaneous systems are the obvious external fixation components or the biological and psychosocial problems of open implants. This project was set up to develop a semi-implantable transcutaneous bone conducting device, introduce it into clinical application and follow-up on the results. Material and Method: The principle of this bone conducting device is the magnetic coupling between implanted and external magnets. After extensive lab tests it was introduced clinically in 2006. Since then there have been performed more than 300 implantations in Recklinghausen and more than 3000 worldwide. Results and Conclusions: The operative technique is relatively simple. With the new "Up-Side-Down-Technique" bone does not have to be removed at all anymore. The 2.6 mm thin implants are hardly palpable. The hearing improvement is similar to other bone conducting hearing aids. This semi-implantable transcutaneous bone conduction hearing device is another option for patients with CSOM, air-bone-gaps, mixed hearing loss or single sided deafness.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.